Valuation
- Market cap
- 58,842,000
- Revenue TTM
- $0
- Net income TTM
- $-45,540,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 121,700
- Avg volume
- 53,868
- Day's range
- $1.86 – $1.95
- Shares out
- 30,488,000
- Stochastic %K
- 16%
- Beta
- 0.79
- Analysts
- Strong Buy
- Price target
- $18.00
Company profile
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the f...
Show more
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 512 386 2900
- Website
- https://www.xbiotech.com
- Address
- 5217 Winnebago Lane, Austin, United States
Latest news
No headlines yet.
